Lundbeck reports positive results from head-to-head study of antidepressant
![Photo: Jens Dresling](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13913797.ece/ALTERNATES/schema-16_9/doc7kil82esvx1ytzm37nc.jpg)
Pharmaceutical firm Lundbeck’s antidepressant vortioxetine, which is sold under brand names Trintellix and Brintellix, has demonstrated an advantage in a head-to-head study against desvenlafaxine, which Pfizer is marketing in the US as Pristiq, Lundbeck has announced in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Lundbeck finds new CFO
For subscribers